Preclinical formulations for discovery and toxicology: physicochemical challenges
暂无分享,去创建一个
[1] S Sweetana,et al. Solubility principles and practices for parenteral drug dosage form development. , 1996, PDA journal of pharmaceutical science and technology.
[2] Dufresne Rg. Skin necrosis from intravenously infused materials. , 1987 .
[3] P. Gao,et al. Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs , 2006, Expert opinion on drug delivery.
[4] Robin Hull,et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes , 2001, Journal of applied toxicology : JAT.
[5] Norman J Barlow,et al. The effect of commonly used vehicles on canine hematology and clinical chemistry values. , 2006, Journal of the American Association for Laboratory Animal Science : JAALAS.
[6] Hyunyoung Jeong,et al. Evaluation of Using Dog as an Animal Model to Study the Fraction of Oral Dose Absorbed of 43 Drugs in Humans , 2000, Pharmaceutical Research.
[7] Beate Bittner,et al. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. , 2002, Current opinion in drug discovery & development.
[8] S. Higuchi,et al. Gastric pH profiles of beagle dogs and their use as an alternative to human testing. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[9] R. Hull. Guideline limit volumes for dosing animals in the preclinical stage of safety evaluation , 1995, Human & experimental toxicology.
[10] A. C. Eissens,et al. The Effects of Cyclodextrins on the Disposition of Intravenously Injected Drugs in the Rat , 1991, Pharmaceutical Research.
[11] I. Gómez-Orellana. Strategies to improve oral drug bioavailability , 2005, Expert opinion on drug delivery.
[12] R. Müller,et al. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.
[13] S. Yalkowsky,et al. Studies in phlebitis. VI: Dilution-induced precipitation of amiodarone HCL. , 1993, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.
[14] S. Venkatesh,et al. Role of the development scientist in compound lead selection and optimization. , 2000, Journal of pharmaceutical sciences.
[15] K. Rex,et al. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. , 2002, Arthritis and rheumatism.
[16] T. Nagai,et al. Enhancement of the oral bioavailability of cinnarizine in oleic acid in beagle dogs. , 1987, Journal of pharmaceutical sciences.
[17] B. Ballard. Biopharmaceutical considerations in subcutaneous and intramuscular drug administration. , 1968, Journal of pharmaceutical sciences.
[18] P. Greengard,et al. The route of absorption of intraperitoneally administered compounds. , 1971, The Journal of pharmacology and experimental therapeutics.
[19] S. Benita,et al. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[20] B. Bittner,et al. The impact of co-solvents and the composition of experimental formulations on the pump rate of the ALZET osmotic pump. , 2000, International journal of pharmaceutics.
[21] Finco Dr,et al. Physiologic effects of rapid infusion of Ringer's lactate solution into dogs. , 1978 .
[22] V. Claassen. Neglected factors in pharmacology and neuroscience research , 1994 .
[23] M. Schleimer,et al. Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. , 2000, International journal of pharmaceutics.
[24] Xujin Lu,et al. pH-Dependent Dissolution in Vitro and Absorption in Vivo of Weakly Basic Drugs: Development of a Canine Model , 2005, Pharmaceutical Research.
[25] E. Kerns,et al. High throughput physicochemical profiling for drug discovery. , 2001, Journal of pharmaceutical sciences.
[26] S. Yalkowsky,et al. Combined effect of cosolvent and cyclodextrin on solubilization of nonpolar drugs. , 1999, Journal of pharmaceutical sciences.
[27] J. Dressman,et al. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. , 1997, Advanced drug delivery reviews.
[28] Monique Alric,et al. A Dynamic Artificial Gastrointestinal System for Studying the Behavior of Orally Administered Drug Dosage Forms Under Various Physiological Conditions , 2004, Pharmaceutical Research.
[29] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[30] J. S. Lee,et al. Biopharmaceutics of Didanosine in Humans and in a Model for Acid-Labile Drugs, the Pentagastrin-Pretreated Dog , 1993, Pharmaceutical Research.
[31] L. Mawdesley-Thomas,et al. The toxicity of dimethyl sulphoxide (DMSO) for the dog, pig, rat and rabbit. , 1975, Toxicology.
[32] E. Masini,et al. Histamine-releasing properties of Polysorbate 80in vitro andin vivo: correlation with its hypotensive action in the dog , 1985, Agents and Actions.
[33] Y C Wang,et al. Review of excipients and pH's for parenteral products used in the United States. , 1980, Journal of the Parenteral Drug Association.
[34] Brian Samas,et al. An intravenous formulation decision tree for discovery compound formulation development. , 2003, International journal of pharmaceutics.
[35] D. Ritchie,et al. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. , 2001, Current topics in medicinal chemistry.
[36] C. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.
[37] P A Wilkinson,et al. Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules. , 1999, International journal of pharmaceutics.
[38] Roger A. Rajewski,et al. Cyclodextrins: Their Future in Drug Formulation and Delivery , 1997, Pharmaceutical Research.
[39] Bradley D. Anderson,et al. Stable Supersaturated Aqueous Solutions of Silatecan 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin via Chemical Conversion in the Presence of a Chemically Modified β-Cyclodextrin , 2002, Pharmaceutical Research.
[40] B. Swanson. Medical use of dimethyl sulfoxide (DMSO). , 1985, Reviews in clinical & basic pharmacology.
[41] Gordon L Amidon,et al. A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.
[42] Susan A Charman,et al. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. , 2006, Journal of pharmaceutical sciences.
[43] G. Sponer,et al. Acute toxicity of various solvents in the mouse and rat. LD50 of ethanol, diethylacetamide, dimethylformamide, dimethylsulfoxide, glycerine, N-methylpyrrolidone, polyethylene glycol 400, 1,2-propanediol and Tween 20. , 1976, Arzneimittel-Forschung.
[44] J. Meyer,et al. Effect of hydroxypropylmethylcellulose on gastrointestinal transit and luminal viscosity in dogs. , 1991, Gastroenterology.
[45] Abdul W Basit,et al. Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. , 2005, International journal of pharmaceutics.
[46] L. Kinter,et al. Characterization of maximal intravenous dose volumes in the dog (Canis familiaris). , 1993, General pharmacology.
[47] P Langguth,et al. Intestinal drug efflux: formulation and food effects. , 2001, Advanced drug delivery reviews.
[48] Rainer H. Müller,et al. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique , 1998 .
[49] T. Darby. Safety evaluation of polymer materials. , 1987, Annual review of pharmacology and toxicology.
[50] W. Curatolo,et al. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings , 1998 .
[51] R. Löbenberg,et al. Evaluation of Various Dissolution Media for Predicting In Vivo Performance of Class I and II Drugs , 1998, Pharmaceutical Research.
[52] Colin W. Pouton,et al. Self-Emulsifying Drug Delivery Systems: Formulation and Biopharmaceutic Evaluation of an Investigational Lipophilic Compound , 2004, Pharmaceutical Research.
[53] Final Report on the Safety Assessment of Propylene Glycol and Polypropylene Glycols , 1994 .
[54] Christopher T. Walsh,et al. Drugs as materials: valuing physical form in drug discovery , 2004, Nature Reviews Drug Discovery.
[55] G. Amidon,et al. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. , 1986, Journal of pharmaceutical sciences.
[56] W. Charman,et al. Lipid-based vehicles for the oral delivery of poorly water soluble drugs , 1997 .
[57] Barrett E. Rabinow,et al. Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.
[58] P. Raymond,et al. Effect of dosing vehicle on the hepatotoxicity of CCl4 and nephrotoxicity of CHCl3 in rats. , 1997, Journal of toxicology and environmental health.
[59] D. Culver,et al. Physiologic effects of rapid infusion of Ringer's lactate solution into dogs. , 1978, American journal of veterinary research.
[60] J. Chaumeil. Micronization: a method of improving the bioavailability of poorly soluble drugs. , 1998, Methods and findings in experimental and clinical pharmacology.
[61] B. D. Anderson,et al. Solubilization of a tripeptide HIV protease inhibitor using a combination of ionization and complexation with chemically modified cyclodextrins. , 1994, Journal of pharmaceutical sciences.
[62] Lawrence X. Yu. An Integrated Model for Determining Causes of Poor Oral Drug Absorption , 1999, Pharmaceutical Research.
[63] V. Baumans,et al. Assessment of side effects induced by injection of different adjuvant/antigen combinations in rabbits and mice , 1998, Laboratory animals.
[64] Alex Sparreboom,et al. Role of Formulation Vehicles in Taxane Pharmacology , 2001, Investigational New Drugs.
[65] N. El-Sherif,et al. Hypotensive Action of Commercial Intravenous Amiodarone and Polysorbate 80 in Dogs , 1982, Journal of cardiovascular pharmacology.
[66] Kap Lim,et al. Solubilization of Thiazolobenzimidazole Using a Combination of pH Adjustment and Complexation with 2-Hydroxypropyl-β-Cyclodextrin , 1993, Pharmaceutical Research.
[67] J. Dressman,et al. Comparison of Canine and Human Gastrointestinal Physiology , 1986, Pharmaceutical Research.
[68] B. Bittner,et al. Formulations and related activities for the oral administration of poorly water-soluble compounds in early discovery animal studies: An overview of frequently applied approaches. Part 1 , 2002 .
[69] C. Kibbey,et al. An integrated process for measuring the physicochemical properties of drug candidates in a preclinical discovery environment. , 2001, Journal of pharmaceutical sciences.
[70] Alexander V. Kabanov,et al. Pluronic P85 Increases Permeability of a Broad Spectrum of Drugs in Polarized BBMEC and Caco-2 Cell Monolayers , 1999, Pharmaceutical Research.
[71] C. Mitchell,et al. Dimethylsulphoxide-induced serum hyperosmolality after cryopreserved stem-cell graft , 1994, The Lancet.
[72] R. Hillman. The subcutaneous space: a route for continuous administration of drugs? , 1983 .